News

   

Last Patient In for landmark PMDD study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announced the last patient was enrolled in the Phase IIb study for its first-in-class compound Sepranolone for premenstrual dysphoric disorder (PMDD). Top-line results are on track for late March 2020.

Full PDF
   

Sepranolone receives FDA IND approval in menstrual migraine

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announces the FDA has approved the IND for its lead compound Sepranolone in menstrual migraine. It is an important confirmation of Sepranolone’s strong safety profile. 

Full PDF
   

Asarina Pharma: Journal of Neuroendocrinology publishes preclinical data on effective Tourette syndrome therapy with no side effects

Stockholm, June 12 2019: A new paper in the Journal of Neuroendocrinology shows how Asarina Pharma’s compound Sepranolone reduced tics in an animal model of Tourette syndrome as effectively as current first-line treatment Haldol—without inducing any motor side effects.

Full PDF
   

Premenstrual Dysphoric Disorder recognized in new WHO International Classification of Diseases ICD-11

Stockholm, June 11, 2019: Premenstrual dysphoric disorder (PMDD) has been given its own classification code and for the first time classified clearly as a gynaecological, not mental, disease in the WHO’s new International Classification of Diseases, ICD-11. “This is a crucial step forward for future diagnosis, treatment and reimbursement of our lead indication” says CEO…

Full PDF
   

Asarina Pharma issues new shares to Ergomed plc

(Stockholm, June 4, 2019) Asarina Pharma AB (publ) today announces that it will, pursuant to the authorisation granted by the Annual General Meeting on 8 May 2019, issue 246,434 new shares to Ergomed plc (“Ergomed”), the CRO carrying out its Phase IIb PMDD study.

Full PDF